-
iPSC-to-RGC Differentiation with Dual SMAD Inhibition
2026-08-31
Chavali and colleagues developed a chemically defined differentiation strategy that combines dual SMAD and canonical Wnt inhibition to generate retinal ganglion cells from induced pluripotent stem cells with improved yield and reproducibility. The workflow produced retinal ganglion cell populations exceeding 80% purity and enabled further enrichment of Thy-1-positive cells, providing a practical platform for glaucoma modeling and retinal regenerative research.
-
Rottlerin Workflows for PKC Signaling Assays
2026-08-30
Rottlerin is a practical PKC inhibitor for dissecting PKC-dependent signaling, cancer-cell responses, apoptosis, endothelial permeability, and virus entry. This guide connects dose selection and assay timing to the clathrin-mediated entry findings reported in grass carp reovirus research, while emphasizing selectivity limits and reproducibility controls.
-
Y-27632: ROCK Inhibition for Translational iPSC Models
2026-08-29
A mechanistic and strategic guide to using Y-27632 as a controlled cytoskeletal perturbation in iPSC-derived airway models, with practical protocol considerations and translational limitations.
-
GS-441524 Workflows for LC–MS/MS Research
2026-08-28
Build more reliable antiviral and pharmacokinetic studies with a workflow that treats GS-441524 as both a biological reagent and a matrix-sensitive analytical target. The approach combines controlled DMSO formulation, parent–metabolite tracking, LC–MS/MS confirmation, and practical troubleshooting for SARS-CoV-2 research.
-
Oleanolic Acid, FXR, and Cholestatic Liver Injury
2026-08-28
The reference study identifies a linked mechanism in which oleanolic acid impairs hepatocyte tight junctions and suppresses FXR-associated bile acid efflux through BSEP and MRP2. Its combined in vivo, in vitro, imaging, and LC-MS/MS strategy provides a useful framework for studying cholestatic drug-induced liver injury and FXR-dependent transport regulation.
-
Quizartinib (AC220) for FLT3 Research
2026-08-27
Quizartinib (AC220) combines low-nanomolar FLT3 activity with a practical workflow for AML signaling, resistance, and xenograft studies. This guide translates its selectivity into assay design, troubleshooting decisions, and cross-disease applications without treating preclinical findings as clinical conclusions.
-
From TIL Biology to Better Fluorescence Data
2026-08-27
Tumor-microenvironment modulation can improve TIL yield and function, but translational decisions depend on measurement quality. This article connects the mechanistic findings of a recent microsphere-enabled TIL study with practical strategies for using the FITC Goat Anti-Mouse IgG (H+L) Antibody in immunofluorescence and flow cytometry, while addressing controls, workflow fit, and preclinical limitations.
-
3-Deazaadenosine hydrochloride: Causal Assay Guide
2026-08-26
3-Deazaadenosine hydrochloride is an S-adenosylhomocysteine hydrolase inhibitor for dissecting methylation-dependent biology. This guide translates recent IGF2BP1–m6A–TUBB4B findings into a rigorous, orthogonal assay strategy for HSC and inflammation research.
-
GPNMB-Based Model Predicts ESCC Immunotherapy Response
2026-08-26
This reference study identifies circulating soluble GPNMB as a biomarker and mechanistic driver of resistance to PD-1 blockade in esophageal squamous cell carcinoma. By integrating plasma GPNMB, CAF-epithelial niche features, and clinicopathological variables, the authors develop a multimodal framework for response and survival prediction.
-
GS-441524: From Prodrug Biology to Assay Design
2026-08-25
Explore how GS-441524 chemistry, bioactivation, and matrix-specific LC–MS/MS analysis shape antiviral research. This guide translates recent prodrug-conversion findings into practical decisions for GS-441524 pharmacokinetics, sample handling, and assay interpretation.
-
3-Deazaadenosine in Reliable Cell Assays
2026-08-25
A scenario-based guide to using 3-Deazaadenosine (SKU B6121) in cell viability, proliferation, cytotoxicity, and methylation studies. It connects assay design, formulation, data interpretation, vendor selection, and preclinical antiviral research to documented mechanistic and product information.
-
Remdesivir (GS-5734): An Assay-First Framework
2026-08-24
Remdesivir (GS-5734) is examined through an assay-first lens that connects polymerase pharmacology with translational antiviral study design. Insights from recent Bourbon virus research clarify how to interpret potency, timing, and tissue-level outcomes without overstating cross-virus evidence.
-
GS-441524: Mechanism, PK, and Research Workflows
2026-08-24
GS-441524 is an adenine nucleoside analog studied for conversion to an active triphosphate antiviral metabolite. Recent LC–MS/MS work maps GS-441524 prodrug conversion across gastric, blood, liver, and animal pharmacokinetic models, while product-specific handling data define solvent, storage, and quality-control requirements.
-
Diphenyleneiodonium chloride for Reliable Assays
2026-08-23
Learn how Diphenyleneiodonium chloride (DPI, SKU B6326) can clarify redox-dependent viability results, cAMP signaling modulation, and oxidative stress experiments. This scenario-based guide covers formulation, controls, protocol optimization, interpretation, and practical product selection.
-
Moxifloxacin Workflows for Gyrase and Toxicity
2026-08-22
Build reproducible Moxifloxacin assays that connect bacterial DNA gyrase inhibition with retinal ganglion cell viability and metabolic-response studies. This guide combines fresh-solution handling, concentration design, mechanistic controls, and troubleshooting for antibiotic toxicity research.